Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

NCT03710291 is registered in ClinicalTrials.gov with Tricida, Inc. as lead sponsor.

NCT NCT03710291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03710291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis
Lead sponsor
Tricida, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
November 20, 2018
Completion date
September 27, 2022
Enrollment
1,480 (actual)
Sites
203

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, metabolic acidosis